ArticleFrontiers in microbiology2022
Heteroresistance Is Associated With
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Systematic review and meta-analysis of colistin heteroresistance in Klebsiella pneumoniae isolates.BMC infectious diseases · 2025Pooled it
- Seeing Bacterial Persistence Through Different Experimental Lenses: How Methodology Shapes Biological Interpretation.Pathogens (Basel, Switzerland) · 2026Review
- Species-dependent in polymyxin B heteroresistance: genomic insights into adaptive evolution in Enterobacteriaceae.Annals of clinical microbiology and antimicrobials · 2026Article
- A nutrient bottleneck controls antibiotic efficacy in structured bacterial populations.Nature communications · 2026Article
- Carbapenemase-directed therapy: optimizing antibiotic combinations against carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Study on the heteroresistance of carbapenem-resistant Klebsiella pneumoniae to Tigecycline and Polymyxin B and antibacterial activity of combined drugs in vitro.BMC microbiology · 2025Article
- Overview of heteroresistance to multiple antibiotics in clinicalJAC-antimicrobial resistance · 2025Article
- Colistin heteroresistance, mechanisms, diagnostic methods, and therapeutic options: A review.Germs · 2025Review
- Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance.Journal of fungi (Basel, Switzerland) · 2025Review
- Article
- Epidemiology, mechanisms, and clinical impact of bacterial heteroresistance.npj antimicrobials and resistance · 2025Review
- Heterogeneous subpopulations inFrontiers in cellular and infection microbiology · 2025Article
- CombatingFrontiers in cellular and infection microbiology · 2025Review
- Recent Advances in Understanding the Clinical Implications of Heterogeneous Drug Resistance inInfection and drug resistance · 2025Review
- Clinical characteristics, molecular epidemiology and mechanisms of colistin heteroresistance inFrontiers in cellular and infection microbiology · 2025Article
- Carbapenem-resistant Gram-negative bacteria exhibiting clinically undetected cefiderocol heteroresistance leads to treatment failure in a murine model of infection.Frontiers in microbiology · 2025Article
- Genome analysis of triple phages that curtails MDR E. coli with ML based host receptor prediction and its evaluation.Scientific reports · 2023Article
- In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.The Journal of antibiotics · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymyxins including polymyxin B and colistin (polymyxin E) are considered the last resort for treating infections caused by carbapenem-resistant gram-negative bacteria. However,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.